Advisor Group Holdings Inc. Sells 27,000 Shares of 22nd Century Group Inc (NYSEAMERICAN:XXII)

Advisor Group Holdings Inc. cut its stake in shares of 22nd Century Group Inc (NYSEAMERICAN:XXII) by 14.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 166,369 shares of the biotechnology company’s stock after selling 27,000 shares during the quarter. Advisor Group Holdings Inc. owned approximately 0.12% of 22nd Century Group worth $127,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in XXII. Raymond James Financial Services Advisors Inc. raised its holdings in 22nd Century Group by 17.0% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 117,035 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 17,000 shares during the period. BNP Paribas Arbitrage SA boosted its stake in 22nd Century Group by 110.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 36,637 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 19,202 shares during the period. Wealthcare Advisory Partners LLC grew its holdings in 22nd Century Group by 187.5% during the 2nd quarter. Wealthcare Advisory Partners LLC now owns 46,000 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 30,000 shares in the last quarter. UBS Group AG raised its position in shares of 22nd Century Group by 31.7% during the first quarter. UBS Group AG now owns 210,612 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 50,699 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of 22nd Century Group by 87.1% in the first quarter. Alliancebernstein L.P. now owns 122,000 shares of the biotechnology company’s stock worth $92,000 after buying an additional 56,800 shares in the last quarter.

Separately, Bradley Woods reiterated a “buy” rating on shares of 22nd Century Group in a research report on Tuesday, August 4th.

XXII stock traded up $0.03 during mid-day trading on Friday, reaching $0.77. 926,189 shares of the stock traded hands, compared to its average volume of 1,388,304. 22nd Century Group Inc has a one year low of $0.55 and a one year high of $2.26.

22nd Century Group (NYSEAMERICAN:XXII) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). The business had revenue of $6.44 million for the quarter, compared to analysts’ expectations of $5.00 million.

22nd Century Group Profile

22nd Century Group, Inc, a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM research cigarettes for use in independent clinical studies.

Featured Article: Cost of Capital Explained

Institutional Ownership by Quarter for 22nd Century Group (NYSEAMERICAN:XXII)

Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.